Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study

Yang, Min1,3; Wang, Wenfei3; Zhang, Peize4; Liu, Guizhen5; Lu, Hailin6; He, Mingjie5; Deng, Guofang2,3; Chen, Xiaoyou1,7

2024

10.2147/IDR.S465075

INFECTION AND DRUG RESISTANCE   影响因子和分区

1178-6973

Objective: We aimed to investigate dysregulated metabolic pathways and identify diagnostic and therapeutic targets in patients with Methods: In our prospective cohort study, plasma samples were collected from healthy individuals, diabetic (DM) patients, untreated TB-only (TB-0)/TB-DM patients (TB-DM-0), and cured TB (TB-6)/TB-DM patients (TB-DM-6) to measure the levels of amino acids, fatty acids, and other metabolites in plasma using high-throughput targeted quantification methods. Results: Significantly different biological processes and biomarkers were identified in DM, TB-DM-0, and TB-DM-6 patients. Moreover, quinolinic acid (QA) showed excellent predictive accuracy for distinguishing between DM patients and TB-DM-0 patients, with an AUC of 1 (95% CI 1-1). When differentiating between TB-DM-0 patients and TB-DM-6 patients, the AUC was 0.9297 (95% CI 0.8460-1). Compared to those in DM patients, the QA levels were significantly elevated in TB-DM-0 patients and decreased significantly after antituberculosis treatment. We simultaneously compared healthy controls and untreated tuberculosis patients and detected an increase in the level of QA in the plasma of tuberculosis patients, which decreased following treatment. Conclusion: These findings improve the current understanding of tuberculosis treatment in patients with diabetes. QA may serve as an ideal diagnostic biomarker for TB-DM patients and contribute to the development of more effective treatments.

pulmonary tuberculosis diabetes metabolomics quinolinic acid biomarker

SCI

英语

通讯

Guangdong Provincial Clinical Research Center for Tuberculosis Project[2020B1111170014] ; Shenzhen Clinical Research Center for Tuberculosis[20210617141509001] ; Shenzhen High-level Hospital Construction Fund[XKJS-CRGRK-008] ; Shenzhen Third People's Hospital Research Fund["24250G1025","G2021010","G2021015","G2021023","G2022155"] ; Shenzhen Scientific and Technological Foundation["KCXFZ20211020163545004","RCJC20221008092726022"]

Infectious Diseases ; Pharmacology & Pharmacy

Infectious Diseases ; Pharmacology & Pharmacy

WOS:001266918900001

DOVE MEDICAL PRESS LTD

Web of Science

1.Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Pharmacol, Beijing, Peoples R China
2.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Dept Pulm Med & TB 2, Shenzhen, Guangdong, Peoples R China
3.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China
4.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Dept Pulm Med & TB 4, Shenzhen, Guangdong, Peoples R China
5.Gannan Med Univ, Ganzhou, Jiangxi, Peoples R China
6.Gannan Med Univ, Ganzhou, Jiangxi, Peoples R China
7.Capital Med Univ, Beijing Ditan Hosp, Infect Dis Dept, Beijing, Peoples R China

Yang, Min,Wang, Wenfei,Zhang, Peize,et al. Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study[J]. INFECTION AND DRUG RESISTANCE,2024,17.

Yang, Min.,Wang, Wenfei.,Zhang, Peize.,Liu, Guizhen.,Lu, Hailin.,...&Chen, Xiaoyou.(2024).Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study.INFECTION AND DRUG RESISTANCE,17.

Yang, Min,et al."Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study".INFECTION AND DRUG RESISTANCE 17(2024).